- Home
- GROW vs ANTX Comparison
GROW vs ANTX Comparison
Compare GROW & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GROW
- ANTX
- Stock Information
- Founded
- GROW 1968
- ANTX 2017
- Country
- GROW United States
- ANTX United States
- Employees
- GROW N/A
- ANTX N/A
- Industry
- GROW Investment Managers
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- GROW Finance
- ANTX Health Care
- Exchange
- GROW Nasdaq
- ANTX Nasdaq
- Market Cap
- GROW 32.9M
- ANTX 37.6M
- IPO Year
- GROW N/A
- ANTX 2022
- Fundamental
- Price
- GROW $2.23
- ANTX $1.41
- Analyst Decision
- GROW
- ANTX Hold
- Analyst Count
- GROW 0
- ANTX 5
- Target Price
- GROW N/A
- ANTX $3.50
- AVG Volume (30 Days)
- GROW 26.7K
- ANTX 168.1K
- Earning Date
- GROW 05-08-2025
- ANTX 03-27-2025
- Dividend Yield
- GROW 4.02%
- ANTX N/A
- EPS Growth
- GROW N/A
- ANTX N/A
- EPS
- GROW 0.04
- ANTX N/A
- Revenue
- GROW $9,421,000.00
- ANTX N/A
- Revenue This Year
- GROW N/A
- ANTX N/A
- Revenue Next Year
- GROW N/A
- ANTX N/A
- P/E Ratio
- GROW $60.71
- ANTX N/A
- Revenue Growth
- GROW N/A
- ANTX N/A
- 52 Week Low
- GROW $2.21
- ANTX $0.87
- 52 Week High
- GROW $2.95
- ANTX $3.88
- Technical
- Relative Strength Index (RSI)
- GROW 16.73
- ANTX 72.16
- Support Level
- GROW $2.27
- ANTX $1.09
- Resistance Level
- GROW $2.35
- ANTX $1.39
- Average True Range (ATR)
- GROW 0.04
- ANTX 0.06
- MACD
- GROW -0.02
- ANTX 0.03
- Stochastic Oscillator
- GROW 5.85
- ANTX 94.20
About GROW U.S. Global Investors Inc.
US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.